Non-Current Assets
Operating Lease Income - 2026 (Lessor)
Neurocrine Biosciences Operating Lease Income - 2026 (Lessor) increased by 14.3% to $4.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 14.3%, from $3.50M to $4.00M. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryProfitability
SignalHigher is better
VolatilityStable
First reportedQ3 2023
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase suggests growth in the bank's operating lease portfolio and recurring revenue potential.
Detailed definition
This represents the future rental income expected from operating leases where the bank acts as the lessor for the 2026 f...
Peer comparison
Common in banks with large commercial equipment or real estate leasing divisions.
Metric ID:
operating_lease_income_2026_lessorHistorical Data
8 periods
| Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|
| Value | $1.70M | $1.70M | $2.70M | $3.50M | $3.50M | $3.50M | $3.50M | $4.00M |
| QoQ Change | — | +0.0% | +58.8% | +29.6% | +0.0% | +0.0% | +0.0% | +14.3% |
| YoY Change | — | — | — | +105.9% | +105.9% | +29.6% | +0.0% | +14.3% |
Range$1.70M – $4.00M
CAGR+63.1%
Avg YoY Growth+51.1%
Median YoY Growth+29.6%
Current Streak7+ quarters growth
Operating Lease Income - 2026 (Lessor) at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's operating lease income - 2026 (lessor)?
- Neurocrine Biosciences (NBIX) reported operating lease income - 2026 (lessor) of $4.00M in Q1 2026.
- How has Neurocrine Biosciences's operating lease income - 2026 (lessor) changed year-over-year?
- Neurocrine Biosciences's operating lease income - 2026 (lessor) increased by 14.3% year-over-year, from $3.50M to $4.00M.
- What does operating lease income - 2026 (lessor) mean?
- The expected rental revenue from operating leases for the year 2026.